Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;12(7):472-482.
doi: 10.1016/S2213-8587(24)00110-4. Epub 2024 May 30.

Causes, prevention, and management of diabetes-related foot ulcers

Affiliations
Review

Causes, prevention, and management of diabetes-related foot ulcers

William Jeffcoate et al. Lancet Diabetes Endocrinol. 2024 Jul.

Abstract

In this Review, we aim to complement the 2023 update of the guidelines of the International Working Group on the Diabetic Foot. We highlight the complexity of the pathological processes that underlie diabetes-related foot ulceration (DFU) and draw attention to the potential implications for clinical management and outcome. Variation observed in the incidence and outcome of DFUs in different communities might result from differences in study populations and the accessibility of care. Comparing differences in incidence, management, and outcome of DFUs in different communities is an essential component of the quality of disease care. Additionally, these comparisons can also highlight the relationship between DFU incidence, management, and outcome and the structure of local clinical services and the availability of staff with the necessary skills. The clinical outcome is, however, also dependent on the availability of multidisciplinary care and the ability of people with DFUs to gain access to that care.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests ES has received payment or honoraria for lectures from AdvanzPharma, Merck Sharp and Dohme, Pfizer, Shionogi, Menarini, and BioMérieux; has received support for attending meetings or travel from AdvanzPharma, Merck Sharp and Dohme, Pfizer, Shionogi, Menarini, and BioMérieux; has participated on the data safety monitoring board or advisory board for AdvanzPharma, Debiopharm, and MicuRx; is an editorial board member for IWGDF; and is chair of the National Diabetes Foot Audit England and Wales. EJB reports grant funding from the National Institutes of Health and US Department of Veterans Affairs; payment or honoraria for lectures, presentations, speakers bureaus, or educational events; support for attending meetings or travel from the Korean Diabetes Association, International Society for the Diabetic Foot Diabetes Association of the ROC (Taiwan), and the American Diabetes Association. FG has received grant funding from the National Institute for Healthcare Research; is an editorial board member of the IWGDF; and is chair for the National Diabetes Foot Audit England and Wales. RF is co-chair for the peripheral artery disease working group of the IWGDF. All other authors declare no competing interests.

Similar articles

Cited by

References

Publication types

LinkOut - more resources